Navigation Links
Aegis Awarded 2nd Patent for Fast Acting Migraine Nasal Spray Treatment
Date:5/14/2013

SAN DIEGO, May 14, 2013 /PRNewswire-iReach/ -- Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,440,631, its second patent providing fast acting formulations for triptans, a class of drugs that are effective in treating migraine headaches which include sumatriptan, zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan and frovatriptan. Human clinical trials have shown that the Intravail® formulation of sumatriptan achieves therapeutic drug levels at approximately 2 to 3 minutes, 20 to 30 times faster that the currently marketed non-injectable sumatriptan products. For comparison, the most widely used triptan formulations, namely sumatriptan nasal spray or tablet formulations, both reach maximum blood levels of drug in about 60 to 120 minutes thus delaying onset of relief.

The enabling Aegis Intravail formulation technology is broadly applicable to a wide range of small molecule and biotherapeutic drugs to increase noninvasive bioavailability by the oral, nasal, buccal, and sublingual routes and to speed attainment of therapeutic drug levels in cases where speed is important to the patient, for example in the treatment of pain, nausea, emesis, convulsive disorders, spasticity, and the like.

Aegis technology is commercialized by our licensees who conduct the actual product development and marketing activities. Aegis' licensees include four of the top 10 largest pharmaceutical companies and two of the top 10 largest generics companies, along with many public and private biotech companies. Aegis growing patent portfolio currently has more than fifty issued and pending drug formulation patents covering peptide, protein, and small-molecule drugs.

About Aegis Therapeutics 
Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability. Our ProTek® excipients stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding the oxidative damage caused by polysorbate surfactants.

For more information about Aegis, please visit: http://www.aegisthera.com.

Press release submitted by Submit Press Release 123.com's press release distribution service

Media Contact:   Ralph Barry , Aegis Therapeutics LLC, 858 618-1400 Ext 102, rbarry@aegisthera.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Aegis Therapeutics LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
2. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
3. BidMed Awarded Equipment Liquidation and Related Services Agreement with the Premier Healthcare Alliance
4. Instrumentation Laboratory Awarded Massachusetts Life Sciences Center Tax Incentive
5. Dr. Isaac Eliaz Awarded Patent for Modified Citrus Pectin and Alginates
6. Creabilis Awarded Prestigious European Commission FP7 Grant to Further Develop its LSE Topical-by-Design Technology
7. Combat Medical Systems Awarded $86 Million DOD Contract
8. Remedium Technologies Inc. Awarded $500,000 Phase II NSF SBIR Grant to Test Sprayable Foam for Stopping Traumatic Bleeding
9. CCS Medical Awarded Medicare Contract
10. GE alliance awarded contract to design new plant-based manufacturing facility in Brazil
11. Hadasit Bio-Holdings Flagship Portfolio Company Enlivex Awarded Orphan Drug Status for ApoCell Treatment by the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)...  Aytu BioScience, Inc. (OTCQX: AYTU), a specialty healthcare ... conditions, announced today that the Company will present its ... on Tuesday, February 16, 2016, at 4:30 p.m. ET.  ... overview of its business and growth strategy, as well ... 31, 2015. --> ...
(Date:2/11/2016)...  Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today, ... Controlled Equity Offering SM Sales Agreement with Cantor ... , Chairman and CEO, stated "During our most recent ... raising money and that we have enough money to ... complete all of our current objectives and nothing has ...
(Date:2/11/2016)... 2016 North America , ... MarketsandMarkets, The global market is expected to reach USD 20,190.1 Million ... CAGR of 10.2%. --> North America , ... by MarketsandMarkets, The global market is expected to reach USD 20,190.1 ... a CAGR of 10.2%. --> According to a new ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... ... industry, ranked among the top five firms in the “2015/2016 Best in KLAS: ... Support and Staffing. KLAS is a research and insights firm on a global ...
(Date:2/11/2016)... ... 2016 , ... In a new paper published in the ... Rod J. Rohrich, and colleagues, examine and underscore the importance of upper lateral ... when addressing this vital area. , The upper lateral cartilage in rhinoplasty, refers ...
(Date:2/11/2016)... ... February 11, 2016 , ... "What holds you back from ... poses a question as a challenge for his readers to examine the full ... Being" (published by Partridge Singapore), Clarke explores the subject with more depth, revealing ...
(Date:2/11/2016)... ... February 11, 2016 , ... Colorado spine surgeon, Donald Corenman, ... 334 spine surgeons to know in 2016 . The list consists of spine surgeons ... surgery. , Dr. Corenman understands the importance of clinical excellence; he has been ...
(Date:2/11/2016)... ... 2016 , ... Dickinson Insurance & Financial Services continues their commitment to act ... of a local boy named Barrett, who has been fighting ALL leukemia for almost ... support for, all local families dealing with childhood cancer. Information on how to help ...
Breaking Medicine News(10 mins):